We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Lays Out First Set of User Fee Rates for Biosimilars
FDA Lays Out First Set of User Fee Rates for Biosimilars
August 14, 2012
Biosimilars makers must dole out nearly $2 million in fees for applications requiring clinical data in fiscal 2013, while companies submitting applications without such data, or supplemental apps, will need to fork over half that amount.